Alzheimer's Disease
22 articles on Alzheimer's Disease, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic Culture: Why Medical Weight Loss Needs Better Guardrails
As semaglutide medications become ubiquitous, we must balance their life-saving cardiovascular benefits with the dangers of normalizing extreme thinness and disordered eating behaviors.
7 min read
GLP-1s and Alzheimer's: Hope, Hype, and the Science of Prevention
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
6 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Beyond Appetite: How GLP-1 Drugs May Be Rewiring the Human Brain
GLP-1 receptor agonists, initially celebrated for revolutionizing diabetes and weight management, are now at the center of an unplanned, massive neuroscience experiment. Emerging data suggests these powerful medications are doing more than just regulating metabolism; they appear to be structurally and functionally altering key brain systems.
7 min read
Beyond Weight Loss: Surprising Health Benefits of GLP-1 Drugs
While widely recognized for their effectiveness in weight management, GLP-1 receptor agonists are revealing a spectrum of profound health benefits. Discover how these groundbreaking medications are impacting cardiovascular health, kidney function, liver disease, and even potentially neurodegenerative conditions.
7 min read
Mediterranean Diet's Cellular Secret: Unlocking Anti-Aging Proteins
A groundbreaking study reveals that the Mediterranean diet may boost cellular health by activating specific mitochondrial microproteins, offering a new perspective on its profound anti-aging benefits.
7 min read
Understanding Insulin Resistance: Beyond Blood Sugar
Insulin resistance is a critical metabolic condition affecting blood sugar regulation and potentially impacting brain function. This comprehensive guide delves into its causes, symptoms, and the vital role of lifestyle interventions.
8 min read
Antimicrobial Peptides: A New Link to Neurodegenerative and Amyloid Diseases
Discover the groundbreaking research linking antimicrobial peptides (AMPs) to neurodegenerative and amyloid diseases. This article delves into the shared mechanisms, bidirectional feedback loops, and potential new therapeutic strategies emerging from this exciting field.
8 min read
GLP-1 Drugs: New Hope for Depression and Motivation?
A recent study published in JAMA Psychiatry has unveiled promising findings regarding GLP-1 receptor agonists, such as semaglutide, and their potential to address a core symptom of major depressive disorder: a lack of motivation. This article delves into the study's methodology, results, and the broader implications for mental health treatment.
8 min read
GLP-1 Drugs: Beyond Weight Loss – New Benefits and Risks Emerge
GLP-1 medications are revolutionizing weight management and diabetes care, but their impact extends far beyond the scale. This article delves into the emerging benefits and potential risks associated with these powerful drugs, offering a comprehensive overview for patients and healthcare providers.
8 min read
Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
5 min read
GLP-1 Microdosers Chase Longevity: Survey Insights
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
5 min read
This Week in Science: Ozempic's Joint Benefits, Superagers Secrets & More
This week's science news uncovers surprising benefits of Ozempic for joint health beyond weight loss, reveals why superagers stay sharp with more new brain neurons, and highlights food quality over diet type for heart protection. From cholesterol-lowering oatmeal diets to a universal nasal vaccine, these findings offer fresh hope for metabolic and cognitive health.
5 min read
Brain Insulin Resistance: Driving Alzheimer's as Type 3 Diabetes
Alzheimer's disease may be more than just amyloid plaques—emerging evidence points to brain insulin resistance as a core driver, earning it the label 'Type 3 diabetes.' A recent Polish study uncovers how impaired insulin signaling starves neurons of energy and accelerates toxic protein buildup. Discover the science and potential therapies like GLP-1 agonists that could change the game.
5 min read
Semaglutide Fails to Slow Alzheimer's Progression in Study
A recent clinical trial, Evoke, investigated semaglutide's potential to slow Alzheimer's disease. While the drug improved certain Alzheimer's-related biomarkers, it did not delay the disease's progression. Researchers emphasize the need for multi-faceted approaches to tackle Alzheimer's.
2 min read
Healthcare Costs in 2026: Some Will Pay More, Others Less
The healthcare landscape will undergo significant changes in 2026. Negotiated Medicare drug prices offer relief to some, but the expiration of Affordable Care Act tax credits and Medicaid uncertainties will increase costs for others.
6 min read
GLP-1 Agonist Market Surge: A Metabolic Shift Transforming Diabetes Treatment and Global Obesity Management
The GLP-1 agonist market is undergoing significant expansion, fundamentally changing how Type 2 Diabetes and obesity are addressed globally. This drug class, initially for glycemic control, has become a key therapeutic option for weight management and cardiovascular risk reduction. The rising popularity of these drugs has sparked a pharmaceutical boom, with focus shifting to advanced agonists offering even greater metabolic advantages.
4 min read
Semaglutide Fails to Slow Advancement of Alzheimer's Disease
Results from a recent trial indicate that semaglutide, typically used for obesity, did not slow the progression of Alzheimer's disease. While the drug improved Alzheimer's-related biomarkers, this did not translate to a delay in the disease's advancement. Researchers emphasize the need for multi-faceted approaches to tackle Alzheimer's.
2 min read
The Heated Race to Dominate the Booming GLP-1 Medication Arena
The GLP-1 drug market is experiencing rapid growth, driven by the increasing demand for treatments for type 2 diabetes and obesity. Three major pharmaceutical companies are vying for market dominance.
3 min read
GLP-1 Weight Loss Drugs: Global Expansion & What It Means for Your Health
GLP-1 drugs are revolutionizing weight loss globally. This post explores the impact of these medications, their potential benefits beyond weight loss, and how to monitor your health on this journey.
4 min read
Gut-Brain Connection: How Gut Health Impacts Neurodegenerative Disease Risk
New research highlights the critical role of the gut-brain-immune axis in neurodegenerative diseases. Understanding this connection could unlock new approaches for prevention and treatment. Read on for key insights!
4 min read
Revolutionizing Drug Discovery: AI and Peptide Therapy for Longevity
Artificial intelligence is revolutionizing the field of peptide therapy, drastically accelerating drug discovery timelines. This is especially promising for tackling complex diseases like Alzheimer's and advancing the field of longevity research.
3 min read